Here are five recent news updates on gastroenterology and endoscopy companies.
AbbVie is expected to release a hepatitis C drug that could compete with the costly, but effective Sovalid and Harvoni treatments from Gilead Science, according to Reuters report.
On Nov. 4, Boston Scientific stock traded at between $13.19 and $13.30 per share, with a 52-week range of $11.10 to $14.08, according to a Jutia Group report.
Cantel Medical acquired International Medical Service S.r.l., a manufacturer of disinfectants used in automated endoscope reprocessors. IMS will be integrated into Cantel Medical's Medivators business unit.
EndoChoice is planning a $100 million to $150 million NASDAQ initial public offering for 2015. The company has yet to file a prospectus for the IPO.
Salix Pharmaceuticals shares have been given an average rating of "buy" from multiple brokerages, according to a Sleek Money report.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.